{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:04:59Z","timestamp":1770822299202,"version":"3.50.1"},"reference-count":110,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2012,3,31]]},"DOI":"10.2217\/fon.12.14","type":"journal-article","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T13:00:41Z","timestamp":1331557241000},"page":"293-305","source":"Crossref","is-referenced-by-count":20,"title":["Systemic Treatment of Malignant Pleural Mesothelioma"],"prefix":"10.1080","volume":"8","author":[{"given":"Federica","family":"Grosso","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, SS. Antonio e Biagio General Hospital, Alessandria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[{"name":"University of Torino, Department of Clinical and Biological Sciences, S. Luigi Hospital, Regione Gonzole, 10, Orbassano (Torino), Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,3,12]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408440903044928"},{"key":"e_1_3_2_3_2_1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the north Western Cape province.","volume":"17","author":"Wagner JC","year":"1960","unstructured":"Wagner JC , SleggsCA, MarchandP. Diffuse pleural mesothelioma and asbestos exposure in the north Western Cape province.Br. J. Ind. Med.17, 260\u2013271 (1960).","journal-title":"Br. J. Ind. Med."},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-007-0016-7"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1179\/oeh.2007.13.4.398"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601638"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh025"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2004.04.001"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.1143"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1cf2b"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.09.009"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3943"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00039510"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5604"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm093"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1728-x"},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70149-8"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.054"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2007.09.039"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60727-8"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj073"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(02)00180-0"},{"issue":"14","key":"e_1_3_2_3_22_1","first-page":"36","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.","volume":"15","author":"Vogelzang NJ","year":"2003","unstructured":"Vogelzang NJ , RusthovenJJ, SymanowskiJet al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 15(14), 36\u201344 (2003).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0837-0"},{"key":"e_1_3_2_3_24_1","article-title":"Effect of folic acid and vitamin B12 supplementation on risk benefit ratio from Phase III study of pemetrexed and cisplatin versus cisplatin in malignant pleural mesothelioma.","volume":"22","author":"Vogelzang NJ","year":"2003","unstructured":"Vogelzang NJ , EmriS, BoyerMJet al. Effect of folic acid and vitamin B12 supplementation on risk benefit ratio from Phase III study of pemetrexed and cisplatin versus cisplatin in malignant pleural mesothelioma. J. Clin. Oncol. 22, Abstract 2644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3190"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm501"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604442"},{"key":"e_1_3_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c73d6"},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20005.14.589"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3027"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)31509-4"},{"key":"e_1_3_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30232"},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.09.018"},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11405"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2003.n.009"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.05.007"},{"issue":"3","key":"e_1_3_2_3_37_1","first-page":"118","article-title":"Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.","volume":"11","author":"Henss H","year":"1998","unstructured":"Henss H , FiebigHH, SchildgeJ, ArnoldH, HasseJ. Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.Onkologie11(3), 118\u2013120 (1998).","journal-title":"Onkologie"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.122"},{"key":"e_1_3_2_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3912"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011139918558"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi187"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.9887"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)30351-8"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c73ec"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.001"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23337"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23313"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.12.004"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.08.011"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.08.031"},{"key":"e_1_3_2_3_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-010-0064-7"},{"key":"e_1_3_2_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9275"},{"key":"e_1_3_2_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605501"},{"key":"e_1_3_2_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9443-1"},{"key":"e_1_3_2_3_55_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.498581"},{"key":"e_1_3_2_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.04.025"},{"key":"e_1_3_2_3_57_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.26.2.f229"},{"key":"e_1_3_2_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.08.012"},{"key":"e_1_3_2_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.10.016"},{"key":"e_1_3_2_3_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1940"},{"key":"e_1_3_2_3_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7634"},{"key":"e_1_3_2_3_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23617"},{"key":"e_1_3_2_3_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31819c8661"},{"key":"e_1_3_2_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690650"},{"key":"e_1_3_2_3_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181d2f008"},{"key":"e_1_3_2_3_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"issue":"18","key":"e_1_3_2_3_67_1","article-title":"Final analysis of a multicenter, double blind, placebo controlled Phase II trial of gemcitabine\/cisplatin (CG) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma.","volume":"25","author":"Karrison T","year":"2007","unstructured":"Karrison T , KindlerHL, GandaraDRet al. Final analysis of a multicenter, double blind, placebo controlled Phase II trial of gemcitabine\/cisplatin (CG) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma. J. Clin. Oncol. 25(Suppl. 18), Abstract 7526 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_3_68_1","article-title":"IFCT-GFPC-0701 MAPS trial, a multicenter randomized Phase II\/III trial of pemetrexed\u2013cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.","volume":"28","author":"Zalcman G","year":"2010","unstructured":"Zalcman G , MargeryJ, ScherpereelAet al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized Phase II\/III trial of pemetrexed\u2013cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J. Clin. Oncol. 28(Suppl. 15), Abstract 7020 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"e_1_3_2_3_69_1","article-title":"Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia Group B (CALGB 30107).","volume":"24","author":"Jahan TM","year":"2006","unstructured":"Jahan TM , GuL, WangXet al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a Phase II study by the Cancer and Leukemia Group B (CALGB 30107). J. Clin. Oncol. 24(18S), Abstract 7081 (2006).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318229586e"},{"key":"e_1_3_2_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.10.005"},{"key":"e_1_3_2_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(03)91684-9"},{"issue":"15","key":"e_1_3_2_3_73_1","article-title":"A multicenter, randomized Phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.","volume":"29","author":"Baas P","year":"2011","unstructured":"Baas P , BuikhuisenW, DalesioOet al. A multicenter, randomized Phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. J. Clin. Oncol. 29(15), Abstract 7006 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec18db"},{"key":"e_1_3_2_3_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.7087"},{"issue":"15","key":"e_1_3_2_3_76_1","article-title":"Final results of a Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).","volume":"28","author":"Nowak AK","year":"2010","unstructured":"Nowak AK , MillwardM, FrancisRJet al. Final results of a Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J. Clin. Oncol. 28(15), Abstract 7036 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087376"},{"key":"e_1_3_2_3_78_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1997"},{"key":"e_1_3_2_3_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.04.010"},{"key":"e_1_3_2_3_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0243-4"},{"key":"e_1_3_2_3_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.069872"},{"key":"e_1_3_2_3_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0052"},{"issue":"15","key":"e_1_3_2_3_83_1","article-title":"Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.","volume":"28","author":"Tsao AS","year":"2010","unstructured":"Tsao AS , WistubaII, MehranRJet al. Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. J. Clin. Oncol. 28(15), Abstract 7042 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"e_1_3_2_3_84_1","article-title":"A Phase II study of dasatinib (D) in patients (pts) with previously treated mesothelioma.","volume":"28","author":"Dudek A","year":"2010","unstructured":"Dudek A , PangH, KratzkeAet al. A Phase II study of dasatinib (D) in patients (pts) with previously treated mesothelioma. J. Clin. Oncol. 28(15), Abstract 7037 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208744"},{"key":"e_1_3_2_3_86_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01578-08"},{"key":"e_1_3_2_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2009.06.027"},{"key":"e_1_3_2_3_88_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3020","article-title":"A first-in-human Phase I study to evaluate GDC-0980, an oral PI3K\/mTOR inhibitor, administered QD in patients with advanced solid tumors.","volume":"29","author":"Wagner AJ","year":"2011","unstructured":"Wagner AJ , BendellJC, DollySet al. A first-in-human Phase I study to evaluate GDC-0980, an oral PI3K\/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 29(Suppl.), Abstract 3020 (2011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_89_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.25.5.4539"},{"key":"e_1_3_2_3_90_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.n.003"},{"key":"e_1_3_2_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(11)70098-3"},{"key":"e_1_3_2_3_92_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037310"},{"key":"e_1_3_2_3_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3649"},{"key":"e_1_3_2_3_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2345"},{"issue":"1","key":"e_1_3_2_3_95_1","first-page":"46","article-title":"Mesothelin targeted cancer immunotherapy.","volume":"44","author":"Hassan R","year":"2008","unstructured":"Hassan R , HoM. Mesothelin targeted cancer immunotherapy.J. Cancer44(1), 46\u201353 (2008).","journal-title":"J. Cancer"},{"key":"e_1_3_2_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.07.016"},{"key":"e_1_3_2_3_97_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031435"},{"key":"e_1_3_2_3_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1592"},{"key":"e_1_3_2_3_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"e_1_3_2_3_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31820db125"},{"key":"e_1_3_2_4_2_1","unstructured":"RARECARE: Surveillance of Rare Cancers in Europe. www.rarecare.eu\/rarecancers\/Rare_Cancers_list_March2011.xls"},{"key":"e_1_3_2_4_3_1","unstructured":"Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01085630?term=NCT01085630&rank=1"},{"key":"e_1_3_2_4_4_1","unstructured":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01064648?term=NCT01064648&rank=1"},{"key":"e_1_3_2_4_5_1","unstructured":"Cisplatin Pemetrexed and Imatinib Mesylate in Malignant Mesothelioma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00402766?term=NCT00402766&rank=1"},{"key":"e_1_3_2_4_6_1","unstructured":"A Phase II Study of the Association of Glivec \u00ae Plus Gemzar \u00ae in Patients With Unresectable Refractory Malignant Mesothelioma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00551252"},{"key":"e_1_3_2_4_7_1","unstructured":"A Phase II Study of the Association of Glivec \u00ae Plus Gemzar \u00ae in Patients With Unresectable Refractory Malignant Mesothelioma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00551252?term=NCT00551252&rank=1"},{"key":"e_1_3_2_4_8_1","unstructured":"Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00770120?term=NCT00770120&rank=1"},{"key":"e_1_3_2_4_9_1","unstructured":"NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01098266"},{"key":"e_1_3_2_4_10_1","unstructured":"Phase II Study of NGR\u2013hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (NGR019). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01358084"},{"key":"e_1_3_2_4_11_1","unstructured":"Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00700336"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.12.14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:41:35Z","timestamp":1719124895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.12.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,12]]},"references-count":110,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3,31]]}},"alternative-id":["10.2217\/fon.12.14"],"URL":"https:\/\/doi.org\/10.2217\/fon.12.14","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,12]]}}}